Sunitinib Malate — Competitive Intelligence Brief

Sunitinib Malate (sunitinib-malate) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Moderate Risk QT Prolonging Agents. Area: Oncology.

marketed Moderate Risk QT Prolonging Agents 3-phosphoinositide-dependent protein kinase 1 Oncology

Target snapshot

Sunitinib Malate (sunitinib-malate) — Pfizer. Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, including PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, and RET.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sunitinib Malate TARGET	sunitinib-malate	Pfizer	marketed	Moderate Risk QT Prolonging Agents	3-phosphoinositide-dependent protein kinase 1	2006-01-01
Sutent	sunitinib	Pfizer	marketed	Moderate Risk QT Prolonging Agents	3-phosphoinositide-dependent protein kinase 1	2006-01-01
celebrex	celebrex	POZEN	marketed		3-phosphoinositide-dependent protein kinase 1, Adenosine receptor A3, Cytochrome c oxidase subunit 2
Simdax	LEVOSIMENDAN		phase 3	Moderate Risk QT Prolonging Agents	Troponin C, slow skeletal and cardiac muscles

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Moderate Risk QT Prolonging Agents class)

1. Pfizer · 2 drugs in this class
2. · 1 drug in this class